Dilated retinal screening, OCT-guided monitoring and timely injections or laser—connected with physician support when blood sugar and related medical risk need closer control.
Diabetes can damage the smallest retinal blood vessels, causing leakage, blockage and—in advanced disease—fragile abnormal vessels. These changes may progress quietly before reading or distance vision is affected.
The macula controls fine central vision. Fluid leaking into it causes diabetic macular oedema, which can occur at different retinopathy stages. Diabetes also raises the risk of cataract and glaucoma, so screening examines the whole eye rather than only taking a retinal photograph.
Bleeding, traction or retinal detachment can develop in advanced diabetic eye disease. Symptoms may occur in one eye while the other still sees normally.
An eye can have mild vessel changes with important macular oedema, or severe peripheral retinopathy before central vision blurs. Both dimensions influence review and treatment.
The retina may look normal even after years of diabetes. A normal examination is reassuring, but it is a baseline rather than a lifetime clearance because retinal changes can develop without symptoms.
Continue diabetes care and return at the interval advised for the diabetes type, pregnancy status, control and other risk factors.
Small retinal vessels may develop microaneurysms, haemorrhages, leakage or areas of reduced blood supply. Vision can remain clear when these changes are away from the macula.
Review becomes more frequent as severity increases. OCT or angiography is added when swelling, reduced vision or treatment planning requires it.
Leaking vessels cause fluid to collect in or near the macula, the retinal area used for reading and fine detail. It can occur at different stages of diabetic retinopathy and may blur or distort central vision.
OCT guides diagnosis and response. Anti-VEGF injections are commonly considered; laser or steroid treatment has a role in selected eyes.
Severe retinal oxygen shortage can trigger fragile new blood vessels. They may bleed into the vitreous or form scar tissue that pulls on the retina, threatening profound vision loss.
Treatment may include pan-retinal photocoagulation, anti-VEGF injections and close follow-up. Vitreoretinal surgery is referred when bleeding or traction requires it.
Not every person needs every test at every visit. The ophthalmologist selects investigations according to vision, retinal stage, macular findings and whether treatment is being considered or monitored.
Arrange a dilated examinationEach eye is tested separately. Changing glucose can temporarily alter focusing power, so a new spectacle prescription may be deferred until blood sugar and refraction are reasonably stable.
Dilating drops allow a wider view of the macula, retinal vessels, optic nerve and peripheral retina. Driving may be difficult afterward, so arrange transport if the team advises it.
Photographs document haemorrhages, exudates, vessel changes and progression. Imaging supports—but does not always replace—a complete clinical examination.
Cross-sectional imaging detects and measures retinal swelling, traction and macular structural change. Repeat scans help judge whether observation or treatment is working.
Dye photographs map leakage, blockage and abnormal vessels. FFA is selected when the result will help clarify disease or guide laser and other treatment.
Diabetes also increases cataract and glaucoma risk. Pressure, lens and the rest of the eye are assessed rather than looking at the retina in isolation.
The plan depends on retinopathy stage, macular swelling, vision, previous response and systemic health. Treatment may stabilise or improve vision, but cannot guarantee recovery of tissue already permanently damaged.
Early disease may not need an eye procedure. The safe review interval depends on stage, macular involvement, pregnancy, systemic control and whether earlier images show change.
Medicine placed into the eye can reduce VEGF-driven leakage and abnormal vessel activity. A course of injections and OCT monitoring may be required rather than a single treatment.
Pan-retinal photocoagulation treats proliferative disease by applying laser to peripheral retina. Focal or grid approaches have a more selective role in macular leakage. Laser protects vision but may have side effects and does not restore every loss.
Steroid injection or implant may be considered for selected diabetic macular oedema, particularly when other treatment is unsuitable or insufficient. Cataract and pressure rise are important considerations.
Persistent vitreous haemorrhage, tractional retinal detachment or complex scar tissue may require vitrectomy by a vitreoretinal surgeon. Timing depends on the anatomy and vision risk.
When sugar, blood pressure or related medical risk needs attention, JEWCC can coordinate physician input on call. The physician manages systemic treatment; the ophthalmologist manages retinal monitoring and eye procedures.
Eye procedures and systemic control are complementary. Do not delay necessary retinal treatment while waiting for a “perfect” sugar value, and do not assume injections or laser make diabetes control less important.
If control or related medical risk needs attention, JEWCC can arrange physician input on call and share the eye-care context needed for a joined-up plan.
Follow the diabetes plan and discuss an individual HbA1c target with the treating physician. Rapid changes in control can also affect refraction and, in some situations, retinopathy monitoring.
High blood pressure adds stress to retinal vessels. Reliable measurement and treatment support both eye and overall vascular health.
Lipids and kidney disease can accompany more severe vascular risk. Share recent reports and medicines with both the physician and eye specialist.
Stopping tobacco and keeping scheduled reviews support long-term risk reduction. Clear vision today does not make future retinal screening optional.
Pregnancy can accelerate pre-existing diabetic retinopathy. When possible, arrange a retinal assessment before conception and inform both the obstetric and eye-care teams. During pregnancy, review frequency is based on the baseline retinal stage and any progression.
Do not change diabetes medicines or postpone eye treatment based only on general online advice. The ophthalmologist, physician and obstetric clinician should weigh the eye findings, maternal health and pregnancy together.
Outpatient consultation, photography, OCT and angiography may have different rules from injections, laser or vitrectomy. Anti-VEGF medicine choice, consumable limits, co-payments and pre-authorisation can affect approval.
JEWCC can help prepare available clinical records, but the insurer or TPA determines eligibility and final approval.
Call before travelling to confirm appointment timing and availability of specific imaging. Dilating drops may blur vision temporarily, so ask whether you should arrange transport.
Jaypuriya Eye and Women Care Centre
Jaypuriya Eye Care Centre
Jaypuriya Eye Care Centre
Yes. Early diabetic retinopathy commonly has no symptoms, and sight can remain clear despite significant peripheral retinal changes. A dilated retinal examination can identify disease before you notice it.
Many people with diabetes are advised at least annual comprehensive dilated eye examinations, but the interval is individual. Retinopathy, pregnancy, recent treatment, poor systemic control or changing findings may require reviews every few months. Follow the ophthalmologist’s written schedule.
Better glucose, blood-pressure and lipid control can reduce the risk of developing or worsening retinopathy, but established retinal damage may not disappear. Eye treatment and medical diabetes treatment address different parts of the same disease and may both be necessary.
Often not. Diabetic macular oedema and proliferative disease may require an initial series followed by OCT-guided intervals. Missing appointments can allow leakage or abnormal vessel activity to return.
Laser is generally used to reduce the risk of serious future loss or control selected leakage. It does not reliably restore vision already lost, and pan-retinal treatment can affect peripheral or night vision. The benefit-risk balance is discussed for the individual eye.
Pregnancy can accelerate diabetic retinopathy, particularly when disease was already present. People with pre-existing diabetes should coordinate eye assessment before pregnancy where possible and early during pregnancy, with follow-up based on retinal findings. Gestational diabetes alone has different screening considerations.
Yes. Eye treatment does not replace systemic diabetes care. When required, JEWCC can coordinate a physician on call to review diabetes control and related medical risk, while the ophthalmology team continues retinal assessment and treatment.
Coverage varies. Consultations, OCT and angiography may be treated differently from injections, laser or surgery. Pre-authorisation and medicine or consumable limits may apply; the insurer or TPA makes the final decision.
